Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

oxycodone

- PMLiVE

FDA approves second over-the-counter naloxone nasal spray for opioid overdose

Over 105,000 fatal opioid overdoses were reported in the US between 2022 and 2023

EU flag

EMA accepts Mundipharma’s application for invasive candidiasis treatment rezafungin

Despite currently available treatments, the mortality rate for patients with invasive candidiasis remains high at up to 40%

- PMLiVE

THE HIDDEN LIFESAVERS: overdose prevention campaign launches nationwide

The campaign encourages people who use drugs to do something remarkable – save a life

Havas Lynx

- PMLiVE

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Will launch Herzuma in seven European countries including the UK and Germany

- PMLiVE

Mundipharma appoints Dr Alberto Martinez as president and CEO

He succeeds Antony Mattessich, who leaves after 12 years with the networked company

- PMLiVE

Mundipharma appoints chief information officer

Philippe Mazas joins the UK-based pharma network from Smith & Nephew

- PMLiVE

When science is not enough

Mundipharma’s Will Dunlop on a new framework to guide development programmes to a better destination

- PMLiVE

Mundipharma to launch first MabThera biosimilar in EU

EMA approves Truxima in all indications licensed to Roche’s cancer drug

- PMLiVE

Study finds no problems switching from Remicade to biosimilar

Findings look to dispel ‘biosimilar resistance’ and encourage greater uptake

- PMLiVE

Remicade biosimilars hit European market

Hospira and Mundipharma begin marketing their version of the blockbuster drug

- PMLiVE

EC gives nod to restless leg syndrome drug Targin

Mundipharma’s medicine is first opioid granted a licence for condition in the EU

- PMLiVE

Successful partnerships in pharma: Skyepharma and Mundipharma

Why skills and flexibility matter more than sheer size

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links